[Pharmacokinetics and clinical studies of a new cephalosporin: cefamandole nafate].
The results of a pharmacokinetic and clinical study of cephamandol naphate indicated that the drug quickly reaches high plasma concentration after both i.m. and i.v. bolus administration. Urinary excretion of the biologically active form is as much as 84--90% of the total dose and mostly takes place in the first 6 hr. The therapeutic response was good: clinical cure in 90%, marked improvement in 6.6%, no change in 3.3%.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002435:Cefamandole / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use*; D002511:Cephalosporins / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009107:Mumps / Q000188:drug therapy; D010031:Otitis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012541:Scarlet Fever / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; D002435:Cefamandole; C012810:cefamandole nafate
Farmacocinetica e clinica di una nuova cefalosporina: cefamandolo nafato.